{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-072312","form_type":"8-K","ticker":"BBOT","cik":"0001869105","company_name":"BridgeBio Oncology Therapeutics, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.461638+00:00","generated_at":"2026-05-17T19:58:40.010228+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Helix retains ~$120M trust (60%+) after redemptions; PIPE adds ~$261M for BBOT deal","bullets":["Retained ~$120M in trust (~60%+ of original) after redemptions; 2nd lowest biotech de-SPAC redemption rate since 2022.","Total expected gross proceeds ~$382M including ~$261M from PIPE led by Cormorant Asset Management and other investors.","Business combination with BridgeBio Oncology Therapeutics (BBOT) expected to close expeditiously, subject to conditions.","Redemption request deadline was July 31, 2025; the low redemption rate signals shareholder support for the deal."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-072312","json":"https://secwatch.observer/filing/0001213900-25-072312.json","markdown":"https://secwatch.observer/filing/0001213900-25-072312.md","text":"https://secwatch.observer/filing/0001213900-25-072312.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025072312/0001213900-25-072312-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1869105/000121390025072312/ea0251994-8k_helix2.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:58:40.010228+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}